Eli Lilly Receives FDA Approval For Olumiant In Pediatric Patients Aged 12 And Older With Severe Alopecia Areata

Eli Lilly and Company has received FDA approval for Olumiant (baricitinib) to treat pediatric patients aged 12 and older with severe alopecia areata (AA). This approval is based on data from the BRAVE-AA-PEDS study, which demonstrated significant scalp hair regrowth and improvements in eyebrows and eyelashes. The approval expands Olumiant's use, which was previously established for adults with rheumatoid arthritis and severe AA.